Trials / Completed
CompletedNCT00698230
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics
Randomized Study to Evaluate the Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB013739 | INCB013739 5 mg QD tablet |
| DRUG | INCB013739 | INCB013739 15 mg QD tablet |
| DRUG | INCB013739 | INCB013739 50 mg QD tablet |
| DRUG | INCB013739 | INCB013739 100 mg QD tablet |
| DRUG | INCB013739 | INCB013739 200 mg QD |
| DRUG | Placebo comparator matching INCB013739 | Orally once daily tablet |
| DRUG | Metformin |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-04-01
- Completion
- 2009-05-01
- First posted
- 2008-06-17
- Last updated
- 2018-02-14
Locations
68 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00698230. Inclusion in this directory is not an endorsement.